Tear Sheet

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Tear Sheet

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. 

Press Releases
Date Title
04/07/21 Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer
03/25/21 Alkermes to Take Part in Stifel's 3rd Annual CNS Day
03/25/21 Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy
03/11/21 Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
03/04/21 Alkermes to Hold Virtual Investor Day
Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Filing date Description

A preliminary proxy statement providing notification matters to be brought to a vote

A preliminary proxy statement providing notification matters to be brought to a vote

A preliminary proxy statement providing notification matters to be brought to a vote

A statement of beneficial ownership of common stock by certain persons

A statement of beneficial ownership of common stock by certain persons